A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD

Trial Profile

A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs NT 503 (Primary) ; Aflibercept
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Therapeutic Use
  • Sponsors GNT Pharma
  • Most Recent Events

    • 08 Jan 2016 Planned number of patients changed from 170 to 110 as per ClinicalTrials.gov record.
    • 08 Jan 2016 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018 as per ClinicalTrials.gov record.
    • 08 Jan 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top